Fortrea Holdings Inc
Veridion Score
Composite trend over time
Why is FTRE moving today?
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for FTRE.
FTRE insider activity
Fortrea Holdings Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$453K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | 2026-06-10 | Morais Mark A. | Insider | sell | $16.82 | 4,674 | 71,365 | $79K | SEC Form 4 |
| 2026-06-12 | 2026-06-10 | Smith David Ross | Insider | sell | $16.34 | 18,244 | 30,117 | $298K | SEC Form 4 |
| 2026-06-03 | 2026-06-02 | Morais Mark A. | Insider | sell | $15.49 | 4,866 | 76,039 | $75K | SEC Form 4 |
| 2026-06-03 | 2026-06-02 | Mcconnell Jill G. | Insider | sell | $15.49 | 4,866 | 78,416 | $75K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | Parks Robert | Insider | sell | $13.44 | 2,000 | 20,389 | $27K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 22 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFTRE contract awards, year to date.
Public federal awards linked to this ticker.
FTRE lobbying filings, year to date.
Registered lobbying filings matched to Fortrea Holdings Inc.